Rapport Therapeutics RAPP Ratios (2024-2026)

NASDAQ RAPP
$46.87 -0.78 (-1.64%)
As of: Sep 4, 2026 · 12:48 PM EDT
Reported Financials

Rapport Therapeutics Quarterly Ratios

Periods 9 quarters
Latest Jun 2026

Rapport Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 9 quarters of results from Jun 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Ratios Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Profitability
EBT Margin -99.29%
EBIT Margin -121.08%
EBITDA Margin -121.08%
Operating Margin -121.08%
Net Margin -99.29%
FCF Margin -65.74%
Efficiency
Assets AverageAssets Avg. 338.62M323.04M308.49M293.77M410.41M523.88M505.01M478.29M
Asset Utilization RatioAsset Util. 0.04
Valuation
Price to EarningsP/E -13.69-42.71-18.41-15.21-15.52-41.84-34.99-75.33-35.30
Price to SalesP/S 74.79
Price to BookP/B 0.742.321.201.281.572.202.443.174.72
Enterprise Value 137.83M709.67M62.62M308.36M359.81M351.89M690.74M620.37M1,562.21M
EV to EBIT -6.63-32.79-2.66-11.38-12.20-11.74-17.94-25.62-25.69
EV to EBITDA -6.63-32.79-2.66-11.38-12.20-11.74-17.94-25.62-25.69
Market Capitalization 248.10M749.09M367.90M366.07M414.98M1,126.56M1,181.27M1,495.90M1,998.29M
Price to FCFP/FCF -14.33-45.25-25.07-17.83-16.54-64.01-47.50-113.78-48.11
EV to FCF -7.96-42.87-4.27-15.02-14.34-19.99-27.77-47.19-37.61
EV to CFO -8.43-43.23-4.33-15.24-14.35-20.15-27.96-47.50-37.68
Return Ratios
Return on Sales [ROS]ROS -121.08%-767.58%
Return on Capital Employed [ROCE]ROCE -22.42%-26.43%-31.12%-36.10%-27.80%-24.78%-25.09%-34.12%
Return on Assets [ROA]ROA -19.03%-21.95%-25.84%-30.06%-23.81%-21.28%-21.24%-28.68%